FrancophonIA/ELRC3.0 huggingface dataset:
English: One Oprymea 1.05 mg prolonged-release tablet, OR two Oprymea 0.52 mg prolonged-release tablets, OR four Oprymea 0.26 mg prolonged-release tablets.
Latvian: Viena Oprymea 1,05 mg ilgstošās darbības tablete, VAI divas Oprymea 0,52 mg ilgstošās darbības tabletes,
English: Oprymea 1.05 mg prolonged-release tablets Pramipexole
Latvian: Oprymea 1,05 mg ilgstošās darbības tabletes Pramipexolum
English: Oprymea 0.35 mg tablets 20 tablets: EU/1/08/469/011 30 tablets: EU/1/08/469/012 60 tablets: EU/1/08/469/013 90 tablets: EU/1/08/469/014 100 tablets: EU/1/08/469/015
Latvian: Oprymea 0,35 mg tabletes 20 tabletes: EU/1/08/469/011 30 tabletes: EU/1/08/469/012 60 tabletes: EU/1/08/469/013 90 tabletes: EU/1/08/469/014 100 tabletes: EU/1/08/469/015
English: 0.26 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Latvian: 0,26 mg: baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P1, ar slīpām malām un iespējamiem plankumiem.
English: Oprymea 1.1 mg tablets 20 tablets: EU/1/08/469/021 30 tablets: EU/1/08/469/022 60 tablets: EU/1/08/469/023 90 tablets: EU/1/08/469/024 100 tablets: EU/1/08/469/025
Latvian: Oprymea 1,1 mg tabletes 20 tabletes: EU/1/08/469/021 30 tabletes: EU/1/08/469/022 60 tabletes: EU/1/08/469/023 90 tabletes: EU/1/08/469/024 100 tabletes: EU/1/08/469/025
English: White, round, with bevelled edges, both sides scored, with imprint "P9" on both halves of one side of the tablet.
Latvian: Baltas, apaļas formas, ar nošķeltām malām un dalījuma līniju abās pusēs, tabletes vienā pusē uz abām dalījuma daļām ir uzdruka „P9”.
English: 1 tablet Oprymea 0.18 mg three times a day OR
Latvian: 1 Oprymea 0,18 mg tablete trīs reizes dienā
English: Oprymea 0.52 mg prolonged-release tablets Pramipexole
Latvian: Oprymea 0,52 mg ilgstošās darbības tabletes Pramipexolum
English: Oprymea 2.1 mg prolonged-release tablets
Latvian: Oprymea 2,1 mg ilgstošās darbības tabletes
English: Take care if you are taking the following medicines: - cimetidine (to treat excess stomach acid and stomach ulcers); - amantadine (which can be used to treat Parkinson's disease); - mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia); - zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system); - cisplatin (to treat various types of cancers); - quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria)); - procainamide (to treat irregular heart beat).
Latvian: - cimetidīnu (mazina pārmērīgu kuņģa skābi un kuņģa čūlu); - amantadīnu (var lietot Parkinsona slimības ārstēšanai); - meksiletīnu (lai ārstētu neregulāru sirdsdarbību - stāvokli, ko sauc par ventrikulāru aritmiju); - zidovudīnu (var lietot iegūtā imūndeficīta sindroma (AIDS) ārstēšanai, cilvēka imūnsistēmas slimība);
English: Mannitol
Latvian: Hipromeloze
English: Each prolonged-release tablet contains 2.1 mg pramipexole (as 3 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra ilgstošās darbības tablete satur 2,1 mg pramipeksola (pramipexolum) (kas atbilst 3 mg pramipeksola dihidrohlorīda monohidrāta).
English: Each prolonged-release tablet contains 3.15 mg pramipexole (as 4.5 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra ilgstošās darbības tablete satur 3,15 mg pramipeksola (pramipexolum) (kas atbilst 4,5 mg pramipeksola dihidrohlorīda monohidrāta).
English: 0.52 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Latvian: 0,52 mg: baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P2, ar slīpām malām un iespējamiem plankumiem.
English: Oprymea 2.62 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/046 30 prolonged-release tablets: EU/1/08/469/047 90 prolonged-release tablets: EU/1/08/469/048 100 prolonged-release tablets: EU/1/08/469/049
Latvian: Oprymea 2,62 mg ilgstošās darbības tabletes 10 ilgstošās darbības tabletes: EU/1/08/469/046 30 ilgstošās darbības tabletes: EU/1/08/469/047 90 ilgstošās darbības tabletes: EU/1/08/469/048 100 ilgstošās darbības tabletes: EU/1/08/469/049
English: Oprymea 2.1 mg prolonged-release tablets Pramipexole
Latvian: Oprymea 2,1 mg ilgstošās darbības tabletes Pramipexolum
English: Each tablet contains 0.35 mg pramipexole (as 0.5 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra tablete satur 0,35 mg pramipeksola (pramipexolum) (kas atbilst 0,5 mg pramipeksola dihidrohlorīda monohidrāta).
English: Remnants in stool
Latvian: Atliekas izkārnījumos
English: Each tablet contains 0.7 mg pramipexole (as 1 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra tablete satur 0,7 mg pramipeksola (pramipexolum) (kas atbilst 1 mg pramipeksola dihidrohlorīda monohidrāta).
English: Common may affect up to 1 in 10 people
Latvian: Bieži var izpausties līdz 1 no 10 cilvēkiem
English: Oprymea 0.26 mg prolonged-release tablets Pramipexole
Latvian: Oprymea 0,26 mg ilgstošās darbības tabletes Pramipexolum
English: Each prolonged-release tablet contains 1.57 mg pramipexole (as 2.25 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra ilgstošās darbības tablete satur 1,57 mg pramipeksola (pramipexolum) (kas atbilst 2,25 mg pramipeksola dihidrohlorīda monohidrāta).
English: Each tablet contains 0.18 mg pramipexole (as 0.25 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra tablete satur 0,18 mg pramipeksola (pramipexolum) (kas atbilst 0,25 mg pramipeksola dihidrohlorīda monohidrāta).
English: EU/1/08/469/011 [20 tablets] EU/1/08/469/012 [30 tablets] EU/1/08/469/013 [60 tablets] EU/1/08/469/014 [90 tablets] EU/1/08/469/015 [100 tablets]
Latvian: EU/1/08/469/011 [20 tabletes] EU/1/08/469/012 [30 tabletes] EU/1/08/469/013 [60 tabletes] EU/1/08/469/014 [90 tabletes] EU/1/08/469/015 [100 tabletes]
English: Oprymea 1.57 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/038 30 prolonged-release tablets: EU/1/08/469/039 90 prolonged-release tablets: EU/1/08/469/040 100 prolonged-release tablets: EU/1/08/469/041
Latvian: Oprymea 1,57 mg ilgstošās darbības tabletes 10 ilgstošās darbības tabletes: EU/1/08/469/038 30 ilgstošās darbības tabletes: EU/1/08/469/039 90 ilgstošās darbības tabletes: EU/1/08/469/040 100 ilgstošās darbības tabletes: EU/1/08/469/041
English: Oprymea 0.7 mg tablets 20 tablets: EU/1/08/469/016 30 tablets: EU/1/08/469/017 60 tablets: EU/1/08/469/018 90 tablets: EU/1/08/469/019 100 tablets: EU/1/08/469/020
Latvian: Oprymea 0,7 mg tabletes 20 tabletes: EU/1/08/469/016 30 tabletes: EU/1/08/469/017 60 tabletes: EU/1/08/469/018 90 tabletes: EU/1/08/469/019 100 tabletes: EU/1/08/469/020
English: EU/1/08/469/021 [20 tablets] EU/1/08/469/022 [30 tablets] EU/1/08/469/023 [60 tablets] EU/1/08/469/024 [90 tablets] EU/1/08/469/025 [100 tablets]
Latvian: EU/1/08/469/021 [20 tabletes] EU/1/08/469/022 [30 tabletes] EU/1/08/469/023 [60 tabletes] EU/1/08/469/024 [90 tabletes] EU/1/08/469/025 [100 tabletes]
English: Oprymea 2.1 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Latvian: Oprymea 2,1 mg ilgstošās darbības tabletes ir baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P4, ar slīpām malām un iespējamiem plankumiem.
English: Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets
Latvian: Oprymea 0,26 mg ilgstošās darbības tabletes Oprymea 0,52 mg ilgstošās darbības tabletes Oprymea 1,05 mg ilgstošās darbības tabletes
English: Each prolonged-release tablet contains 1.05 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra ilgstošās darbības tablete satur 1,05 mg pramipeksola (pramipexolum) (kas atbilst 1,5 mg pramipeksola dihidrohlorīda monohidrāta).
English: Oprymea 1.05 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Latvian: Oprymea 1,05 mg ilgstošās darbības tabletes ir baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P3, ar slīpām malām un iespējamiem plankumiem.
English: Oprymea 2.1 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/042 30 prolonged-release tablets: EU/1/08/469/043 90 prolonged-release tablets: EU/1/08/469/044 100 prolonged-release tablets: EU/1/08/469/045
Latvian: Oprymea 2,1 mg ilgstošās darbības tabletes 10 ilgstošās darbības tabletes: EU/1/08/469/042 30 ilgstošās darbības tabletes: EU/1/08/469/043 90 ilgstošās darbības tabletes: EU/1/08/469/044 100 ilgstošās darbības tabletes: EU/1/08/469/045
English: Oprymea 1.57 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Latvian: Oprymea 1,57 mg ilgstošās darbības tabletes ir baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P12, ar slīpām malām un iespējamiem plankumiem.
English: Oprymea 0.26 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/026 30 prolonged-release tablets: EU/1/08/469/027 90 prolonged-release tablets: EU/1/08/469/028 100 prolonged-release tablets: EU/1/08/469/029
Latvian: Oprymea 0,26 mg ilgstošās darbības tabletes 10 ilgstošās darbības tabletes: EU/1/08/469/026 30 ilgstošās darbības tabletes: EU/1/08/469/027 90 ilgstošās darbības tabletes: EU/1/08/469/028 100 ilgstošās darbības tabletes: EU/1/08/469/029
English: Oprymea 1.05 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/034 30 prolonged-release tablets: EU/1/08/469/035 90 prolonged-release tablets: EU/1/08/469/036 100 prolonged-release tablets: EU/1/08/469/037
Latvian: Oprymea 1,05 mg ilgstošās darbības tabletes 10 ilgstošās darbības tabletes: EU/1/08/469/034 30 ilgstošās darbības tabletes: EU/1/08/469/035 90 ilgstošās darbības tabletes: EU/1/08/469/036 100 ilgstošās darbības tabletes: EU/1/08/469/037
English: Oprymea 0.18 mg tablets 20 tablets: EU/1/08/469/006 30 tablets: EU/1/08/469/007 60 tablets: EU/1/08/469/008 90 tablets: EU/1/08/469/009 100 tablets: EU/1/08/469/010
Latvian: Oprymea 0,18 mg tabletes 20 tabletes: EU/1/08/469/006 30 tabletes: EU/1/08/469/007 60 tabletes: EU/1/08/469/008 90 tabletes: EU/1/08/469/009
English: Oprymea 0.52 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Latvian: Oprymea 0,52 mg ilgstošās darbības tabletes ir baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P2, ar slīpām malām un iespējamiem plankumiem.
English: EU/1/08/469/001[20 tablets] EU/1/08/469/002 [30 tablets] EU/1/08/469/003 [60 tablets] EU/1/08/469/004 [90 tablets] EU/1/08/469/005 [100 tablets]
Latvian: EU/1/08/469/001 [20 tabletes] EU/1/08/469/002 [30 tabletes] EU/1/08/469/003 [60 tabletes] EU/1/08/469/004 [90 tabletes] EU/1/08/469/005 [100 tabletes]
English: Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly with Oprymea.
Latvian: Ja šādas zāles ordinē vienlaikus ar Oprymea, jāapsver pramipeksola devas mazināšanas nepieciešamība.
English: EU/1/08/469/042 [10 prolonged-release tablets] EU/1/08/469/043 [30 prolonged-release tablets] EU/1/08/469/044 [90 prolonged-release tablets] EU/1/08/469/045 [100 prolonged-release tablets]
Latvian: EU/1/08/469/042 [10 ilgstošās darbības tabletes] EU/1/08/469/043 [30 ilgstošās darbības tabletes] EU/1/08/469/044 [90 ilgstošās darbības tabletes] EU/1/08/469/045 [100 ilgstošās darbības tabletes]
English: EU/1/08/469/006 [20 tablets] EU/1/08/469/007 [30 tablets] EU/1/08/469/008 [60 tablets] EU/1/08/469/009 [90 tablets] EU/1/08/469/010 [100 tablets]
Latvian: EU/1/08/469/006 [20 tabletes] EU/1/08/469/007 [30 tabletes] EU/1/08/469/008 [60 tabletes] EU/1/08/469/009 [90 tabletes] EU/1/08/469/010 [100 tabletes]
English: EU/1/08/469/016 [20 tablets] EU/1/08/469/017 [30 tablets] EU/1/08/469/018 [60 tablets] EU/1/08/469/019 [90 tablets] EU/1/08/469/020 [100 tablets]
Latvian: EU/1/08/469/016 [20 tabletes] EU/1/08/469/017 [30 tabletes] EU/1/08/469/018 [60 tabletes] EU/1/08/469/019 [90 tabletes] EU/1/08/469/020 [100 tabletes]
English: - Hyperkinesia (increased movements and inability to keep still) - Weight increase - Allergic reactions (e.g. rash, itching, hypersensitivity) - Fainting - Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)* - Inappropriate antidiuretic hormone secretion* - Restlessness - Dyspnoea (difficulties to breathe) - Hiccups - Pneumonia (infection of the lungs) - Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
Latvian: - Murgi - Pārmērīga miegainība dienas laikā un pēkšņas iemigšanas epizodes - Amnēzija (atmiņas traucējumi) - Hiperkinēzija (palielināts kustīgums un nespēja palikt mierā) - Ķermeņa masas palielināšanās - Alerģiskas reakcijas (piemēram, izsitumi, nieze, paaugstinātas jutības reakcijas) - Ģībonis - Sirds mazspēja (sirdsdarbības traucējumi, kas var izraisīt elpas trūkumu vai potīšu pietūkumu)*
English: EU/1/08/469/050 [10 prolonged-release tablets] EU/1/08/469/051 [30 prolonged-release tablets] EU/1/08/469/052 [90 prolonged-release tablets] EU/1/08/469/053 [100 prolonged-release tablets]
Latvian: EU/1/08/469/050 [10 ilgstošās darbības tabletes] EU/1/08/469/051 [30 ilgstošās darbības tabletes] EU/1/08/469/052 [90 ilgstošās darbības tabletes] EU/1/08/469/053 [100 ilgstošās darbības tabletes]
English: What Oprymea looks like and contents of the pack Oprymea 0.088 mg tablets are white, round, with bevelled edges and imprint "P6" on one side of the tablet.
Latvian: Oprymea 0,088 mg tabletes ir baltas, apaļas formas, ar nošķeltām malām un uzdruku „P6” vienā tabletes pusē.
English: EU/1/08/469/026 [10 prolonged-release tablets] EU/1/08/469/027 [30 prolonged-release tablets] EU/1/08/469/028 [90 prolonged-release tablets] EU/1/08/469/029 [100 prolonged-release tablets]
Latvian: EU/1/08/469/026 [10 ilgstošās darbības tabletes] EU/1/08/469/027 [30 ilgstošās darbības tabletes] EU/1/08/469/028 [90 ilgstošās darbības tabletes] EU/1/08/469/029 [100 ilgstošās darbības tabletes]
English: Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra ilgstošās darbības tablete satur 0,26 mg pramipeksola (pramipexolum) (kas atbilst 0,375 mg pramipeksola dihidrohlorīda monohidrāta).
English: Oprymea 0.52 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/030 30 prolonged-release tablets: EU/1/08/469/031 90 prolonged-release tablets: EU/1/08/469/032 100 prolonged-release tablets: EU/1/08/469/033
Latvian: Oprymea 0,52 mg ilgstošās darbības tabletes 10 ilgstošās darbības tabletes: EU/1/08/469/030 30 ilgstošās darbības tabletes: EU/1/08/469/031 90 ilgstošās darbības tabletes: EU/1/08/469/032 100 ilgstošās darbības tabletes: EU/1/08/469/033
English: EU/1/08/469/034 [10 prolonged-release tablets] EU/1/08/469/035 [30 prolonged-release tablets] EU/1/08/469/036 [90 prolonged-release tablets] EU/1/08/469/037 [100 prolonged-release tablets]
Latvian: EU/1/08/469/034 [10 ilgstošās darbības tabletes] EU/1/08/469/035 [30 ilgstošās darbības tabletes] EU/1/08/469/036 [90 ilgstošās darbības tabletes] EU/1/08/469/037 [100 ilgstošās darbības tabletes]
English: EU/1/08/469/046 [10 prolonged-release tablets] EU/1/08/469/047 [30 prolonged-release tablets] EU/1/08/469/048 [90 prolonged-release tablets] EU/1/08/469/049 [100 prolonged-release tablets]
Latvian: EU/1/08/469/046 [10 ilgstošās darbības tabletes] EU/1/08/469/047 [30 ilgstošās darbības tabletes] EU/1/08/469/048 [90 ilgstošās darbības tabletes] EU/1/08/469/049 [100 ilgstošās darbības tabletes]
English: EU/1/08/469/030 [10 prolonged-release tablets] EU/1/08/469/031[30 prolonged-release tablets] EU/1/08/469/032[90 prolonged-release tablets] EU/1/08/469/033[100 prolonged-release tablets]
Latvian: EU/1/08/469/030 [10 ilgstošās darbības tabletes] EU/1/08/469/031 [30 ilgstošās darbības tabletes] EU/1/08/469/032 [90 ilgstošās darbības tabletes] EU/1/08/469/033 [100 ilgstošās darbības tabletes]
English: EU/1/08/469/038 [10 prolonged-release tablets] EU/1/08/469/039 [30 prolonged-release tablets] EU/1/08/469/040 [90 prolonged-release tablets] EU/1/08/469/041 [100 prolonged-release tablets]
Latvian: EU/1/08/469/038 [10 ilgstošās darbības tabletes] EU/1/08/469/039 [30 ilgstošās darbības tabletes] EU/1/08/469/040 [90 ilgstošās darbības tabletes] EU/1/08/469/041 [100 ilgstošās darbības tabletes]
English: Gastrointestinal disorders nausea constipation vomiting
Latvian: Kuņģa- zarnu trakta traucējumi
English: 1 tablet Oprymea 0.35 mg OR
Latvian: 1 Oprymea 0,35 mg tablete
English: Vascular disorders hypotension
Latvian: Kompulsīva pārēšanās Hiperfāgija
English: Each prolonged-release tablet contains 0.52 mg pramipexole (as 0.75 mg pramipexole dihydrochloride monohydrate).
Latvian: Katra ilgstošās darbības tablete satur 0,52 mg pramipeksola (Pramipexolum) (kas atbilst 0,75 mg pramipeksola dihidrohlorīda monohidrāta).
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Latvian: Baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P3, ar slīpām malām un iespējamiem plankumiem.
English: 1 tablet Oprymea 0.088 mg 1 tablet Oprymea 1.1 mg three three times a day times a day
Latvian: 1 Oprymea 1,1 mg tablete trīs reizes dienā
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Latvian: Baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P4, ar slīpām malām un iespējamiem plankumiem.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Latvian: Baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P1, ar slīpām malām un iespējamiem plankumiem.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Latvian: Baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P12, ar slīpām malām un iespējamiem plankumiem.
English: Dose Schedule of Oprymea Titration Step Once Daily Evening Dose
Latvian: Oprymea dozēšanas shēma Titrēšanas solis
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Latvian: Baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P2, ar slīpām malām un iespējamiem plankumiem.
English: Furthermore a reduction of the dose or termination of therapy may be considered.
Latvian: Ja attīstās šādi simptomi, jāapsver devas samazināšana vai pakāpeniska zāļu lietošanas pārtraukšana.
English: Oprymea 3.15 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/050 30 prolonged-release tablets: EU/1/08/469/051 90 prolonged-release tablets: EU/1/08/469/052 100 prolonged-release tablets: EU/1/08/469/053
Latvian: 10 ilgstošās darbības tabletes: EU/1/08/469/050 30 ilgstošās darbības tabletes: EU/1/08/469/051 90 ilgstošās darbības tabletes: EU/1/08/469/052 100 ilgstošās darbības tabletes: EU/1/08/469/053
English: România KRKA Romania S.R.L., Bucharest
Latvian: E. J. Busuttil Ltd.
English: What Oprymea looks like and contents of the pack Oprymea 0.26 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Latvian: Oprymea 0,26 mg ilgstošās darbības tabletes ir baltas vai gandrīz baltas, apaļas (diametrs 10 mm), nedaudz abpusēji izliektas tabletes ar vienā pusē iegravētu P1, ar slīpām malām un iespējamiem plankumiem.
English: sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).
Latvian: - Pēc Oprymea terapijas pārtraukšanas vai devas samazināšanas var rasties nomākts garastāvoklis, apātija, trauksme, nogurums, svīšana vai sāpes (to sauc par dopamīna agonistu atcelšanas sindromu - DAAS).
English: Renal impairment
Latvian: Aizdusa Žagas
English: This overview was last updated in 03-2019.
Latvian: Šis kopsavilkums pēdējo reizi atjaunināts 2019.03.
English: Further information on Viread can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/viread.
Latvian: Sīkāka informācija par Viread ir atrodama aģentūras tīmekļa vietnē: ema.europa.eu/medicines/human/EPAR/viread.
English: What measures are being taken to ensure the safe and effective use of Viread?
Latvian: Kas tiek darīts, lai garantētu drošu un efektīvu Viread lietošanu?
English: As for all medicines, data on the use of Viread are continuously monitored.
Latvian: Tāpat kā par visām zālēm, dati par Vireadlietošanu tiek pastāvīgi uzraudzīti.
English: Viread received a marketing authorisation valid throughout the EU on 5 February 2002.
Latvian: 2002. gada 5. februārī Viread saņēma reģistrācijas apliecību, kas derīga visā ES.
English: Viread is used in combination with other HIV medicines.
Latvian: Viread lieto kombinācijā ar citām HIV zālēm.
English: Other information about Viread:
Latvian: Cita informācija par Viread
English: An overview of Viread and why it is authorised in the EU
Latvian: Viread pārskats un kāpēc tās ir reģistrētas ES
English: Viread, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Latvian: Viread, kad tās lieto kopā ar citām pretvīrusu zālēm, samazina HIV daudzumu asinīs un uztur to zemā līmenī.
English: Side effects reported with Viread are carefully evaluated and any necessary action taken to protect patients.
Latvian: Ziņotās ar Viread lietošanu saistītās blakusparādības tiek rūpīgi izvērtētas, un tiek veikti visi pacientu aizsardzībai nepieciešamie pasākumi.
English: What benefits of Viread have been shown in studies?
Latvian: Kādi Viread ieguvumi atklāti pētījumos?
English: Viread does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Latvian: Viread neizārstē ne HIV infekciju, ne arī AIDS, bet tās var palēnināt bojājumus imūnsistēmā un ar AIDS saistītu infekciju un slimību attīstību.
English: Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI).
Latvian: Tenofovīrs ir nukleozīdu reversās transkriptāzes inhibitors (NRTI).
English: The European Medicines Agency decided that Viread's benefits are greater than its risks and it can be authorised for use in the EU.
Latvian: Eiropas Zāļu aģentūra nolēma, ka ieguvums, lietojot Viread, pārsniedz šo zāļu radīto risku, un zāles var reģistrēt lietošanai ES.
English: For the treatment of HIV, Viread was more effective than placebo (a dummy treatment) when added to existing treatment.
Latvian: HIV ārstēšanā Viread bija efektīvākas nekā placebo (fiktīva ārstēšana), kad tās pievienoja jau esošajai ārstēšanai.
English: Viread (tenofovir disoproxil)
Latvian: Viread (tenofovīra dizoproksils)
English: The figure for the combination treatment of Viread and emtricitabine was 88%.
Latvian: Rādītājs, ko veido Viread un emtricitabīna lietošana kopā, bija 88 %.